Exelixis (EXEL) Return on Capital Employed (2011 - 2026)
Exelixis' (EXEL) quarterly Return on Capital Employed came in at 39.89% in Q2 2026, up 933.0% year-on-year from 3.86% in Q2 2025, and up 11.07% quarter-over-quarter from 35.92% in Q1 2026.
Exelixis (EXEL) Return on Capital Employed (2011 - 2026) Analysis & Trends
Exelixis' Return on Capital Employed history runs 16 years deep, the most recent figure standing at 39.89% for Q2 2026.
- On a quarterly basis, Return on Capital Employed rose 933.0% year-over-year to 39.89% in Q2 2026; TTM through Apr 2026 was 39.89%, a 933.0% increase from a year earlier, with the FY2026 full-year figure at 35.02%, up 1123.0% from the prior year.
- Return on Capital Employed rose to 39.89% in Q2 2026 per EXEL's latest filing, from 35.92% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 39.89% in Q2 2026 and bottomed at 1.53% in Q3 2023.
- The 5-year median for Return on Capital Employed is 16.71% (2022), against an average of 18.47%.
- Across the five-year window, Return on Capital Employed sank 1518 bps in 2023 and surged 2370 bps in 2025, its largest moves.
- Year by year, Return on Capital Employed stood at 7.48% in 2022, then dropped by 11 bps to 6.66% in 2023, then jumped by 218 bps to 21.16% in 2024, then jumped by 59 bps to 33.66% in 2025, then grew by 19 bps to 39.89% in 2026.
- Per Business Quant, the three latest EXEL Return on Capital Employed figures stand at 39.89% (Q2 2026), 35.92% (Q1 2026), and 33.66% (Q4 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,102.16 Bn | 67,101.87 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,908.96 Bn | 1,908.90 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | -107.40% |
| 4 | BeOne Medicines | 474.03 Bn | 469.24 Bn | 1.35 Bn | 10.46% |
| 5 | Vertex Pharmaceuticals | 122.13 Bn | 114.88 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 70.09 Bn | 61.34 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - | - |
| 8 | Argenx Se | 55.96 Bn | 50.77 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.53 Bn | 34.52 Bn | 959.66 Mn | 20.34% |
| 10 | Exelixis | 14.50 Bn | 13.72 Bn | 590.86 Mn | 39.89% |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 3, 2026 | 39.89% |
| Jan 2, 2026 | 35.92% |
| Oct 3, 2025 | 33.66% |
| Jul 4, 2025 | 28.90% |
| Apr 4, 2025 | 30.56% |
| Jan 3, 2025 | 23.71% |
| Sep 27, 2024 | 21.16% |
| Jun 28, 2024 | 15.13% |
| Mar 29, 2024 | 6.86% |
| Dec 29, 2023 | 6.66% |
| Sep 29, 2023 | 1.53% |
| Jun 30, 2023 | 5.04% |
| Mar 31, 2023 | 5.29% |
| Dec 30, 2022 | 7.48% |
| Sep 30, 2022 | 16.71% |
| Jul 1, 2022 | 16.51% |
| Apr 1, 2022 | 19.01% |
| Dec 31, 2021 | 16.32% |
| Oct 1, 2021 | 9.09% |
| Jul 2, 2021 | 4.95% |